Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

15-Year study tracks hidden risks of CAR-T cancer therapy

NCT ID NCT02445222

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 1,400 people who previously received CAR-T cell therapy for cancer. Researchers will monitor them for 15 years to check for delayed side effects like new cancers, infections, or immune disorders. The goal is to understand the long-term safety of this gene-based treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lentiviral-based CAR-T cell therapy
What this could lead to
If successful, this study will confirm the long-term safety of CAR-T therapy, helping doctors better understand risks and benefits for future patients.
What could go wrong
This is a follow-up study, not a treatment trial, so it won't directly help participants. It may find rare or unexpected side effects over 15 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2015

Expected to finish

Feb 2036

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients who have received a CAR-T therapy and completed or discontinued early from a Novartis sponsored treatment protocol that utilized CAR-T cells or from any CAR-T trial sponsored by the University of Pennsylvania with which Novartis has a contractual agreement to co-develop the CAR technology. * Patients who have provided informed consent for the long term follow up study prior to their study participation . Exclusion Criteria: * There are no specific exclusion criteria for this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long term safety of patients receiving car-T in an eligible clinical trial or managed access program are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long term safety of patients receiving car-T in an eligible clinical trial or managed access program

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    109 sites in 22 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beth Israel Deaconess Med Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Children s Mercy Hospital

    RECRUITING

    Kansas City, Missouri, 64108, United States

  • Children's Mercy Hospital SC

    RECRUITING

    Kansas City, Missouri, 64108, United States

  • Childrens Healthcare of Atlanta

    RECRUITING

    Atlanta, Georgia, 30342, United States

  • Childrens Hospital Los Angeles

    RECRUITING

    Los Angeles, California, 90027, United States

  • Cincinnati Children's Hospital Medical Center

    RECRUITING

    Cincinnati, Ohio, 45229-3039, United States

  • Cinn Children Hosp Medical Center

    RECRUITING

    Cincinnati, Ohio, 45229-3039, United States

  • City of Hope National Medical Center

    RECRUITING

    Duarte, California, 91010 3000, United States

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Duke Unversity Medical Center

    RECRUITING

    Durham, North Carolina, 27705, United States

  • Duke Unversity Medical Center SC - CTL019B2205J

    RECRUITING

    Durham, North Carolina, 27705, United States

  • Emory University School of Medicine-Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Emory University School of Medicine/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • MD Anderson Cancer Center SC

    RECRUITING

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic Arizona

    COMPLETED

    Phoenix, Arizona, 85054, United States

  • Novartis Investigative Site

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Novartis Investigative Site

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Novartis Investigative Site

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Novartis Investigative Site

    WITHDRAWN

    Parkville, Victoria, 3052, Australia

  • Novartis Investigative Site

    RECRUITING

    Murdoch, Western Australia, 6150, Australia

  • Novartis Investigative Site

    RECRUITING

    Herston, QLD 4006, Australia

  • Novartis Investigative Site

    WITHDRAWN

    Linz, 4020, Austria

  • Novartis Investigative Site

    RECRUITING

    Salzburg, 5020, Austria

  • Novartis Investigative Site

    RECRUITING

    Vienna, 1090, Austria

  • Novartis Investigative Site

    RECRUITING

    Vienna, A 1090, Austria

  • Novartis Investigative Site

    RECRUITING

    Ghent, 9000, Belgium

  • Novartis Investigative Site

    RECRUITING

    Hamilton, Ontario, L8V 1C3, Canada

  • Novartis Investigative Site

    RECRUITING

    Toronto, Ontario, M5G 1X8, Canada

  • Novartis Investigative Site

    RECRUITING

    Montreal, Quebec, H1T 2M4, Canada

  • Novartis Investigative Site

    RECRUITING

    Montreal, Quebec, H3T 1C5, Canada

  • Novartis Investigative Site

    RECRUITING

    Beijing, 100036, China

  • Novartis Investigative Site

    RECRUITING

    Copenhagen, DK-2100, Denmark

  • Novartis Investigative Site

    RECRUITING

    Helsinki, 00029, Finland

  • Novartis Investigative Site

    RECRUITING

    Nantes, 44093, France

  • Novartis Investigative Site

    RECRUITING

    Paris, 75019, France

  • Novartis Investigative Site

    RECRUITING

    Paris, 75475, France

  • Novartis Investigative Site

    RECRUITING

    Pierre-Bénite, 69495, France

  • Novartis Investigative Site

    RECRUITING

    Villejuif, 94800, France

  • Novartis Investigative Site

    RECRUITING

    Munich, Bavaria, 81377, Germany

  • Novartis Investigative Site

    RECRUITING

    Regensburg, Bavaria, 93053, Germany

  • Novartis Investigative Site

    RECRUITING

    Würzburg, Bavaria, 97080, Germany

  • Novartis Investigative Site

    RECRUITING

    Frankfurt am Main, Hesse, 60590, Germany

  • Novartis Investigative Site

    RECRUITING

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Novartis Investigative Site

    RECRUITING

    Leipzig, Saxony, 04103, Germany

  • Novartis Investigative Site

    RECRUITING

    Berlin, 13353, Germany

  • Novartis Investigative Site

    RECRUITING

    Hamburg, 20246, Germany

  • Novartis Investigative Site

    RECRUITING

    Ulm, 89081, Germany

  • Novartis Investigative Site

    RECRUITING

    Chaïdári, 124 62, Greece

  • Novartis Investigative Site

    RECRUITING

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    RECRUITING

    Ramat Gan, 5265601, Israel

  • Novartis Investigative Site

    RECRUITING

    Tel Aviv, 6423906, Israel

  • Novartis Investigative Site

    RECRUITING

    Bologna, BO, 40138, Italy

  • Novartis Investigative Site

    RECRUITING

    Monza, MB, 20900, Italy

  • Novartis Investigative Site

    RECRUITING

    Milan, MI, 20132, Italy

  • Novartis Investigative Site

    RECRUITING

    Milan, MI, 20133, Italy

  • Novartis Investigative Site

    RECRUITING

    Rozzano, MI, 20089, Italy

  • Novartis Investigative Site

    RECRUITING

    Roma, RM, 00165, Italy

  • Novartis Investigative Site

    RECRUITING

    Roma, RM, 00168, Italy

  • Novartis Investigative Site

    RECRUITING

    Fukuoka, Fukuoka, 812-8582, Japan

  • Novartis Investigative Site

    RECRUITING

    Sapporo, Hokkaido, 060 8648, Japan

  • Novartis Investigative Site

    RECRUITING

    Sendai, Miyagi, 980 8574, Japan

  • Novartis Investigative Site

    WITHDRAWN

    Chuo Ku, Tokyo, 104 0045, Japan

  • Novartis Investigative Site

    RECRUITING

    Kyoto, 606 8507, Japan

  • Novartis Investigative Site

    COMPLETED

    Amsterdam, North Holland, 1105 AZ, Netherlands

  • Novartis Investigative Site

    COMPLETED

    Utrecht, 3584 CS, Netherlands

  • Novartis Investigative Site

    WITHDRAWN

    Utrecht, 3584 CX, Netherlands

  • Novartis Investigative Site

    RECRUITING

    Oslo, 0310, Norway

  • Novartis Investigative Site

    RECRUITING

    Oslo, 0424, Norway

  • Novartis Investigative Site

    RECRUITING

    Riyadh, 11211, Saudi Arabia

  • Novartis Investigative Site

    RECRUITING

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    RECRUITING

    Singapore, 169608, Singapore

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 06351, South Korea

  • Novartis Investigative Site

    RECRUITING

    Esplugues, Barcelona, 08950, Spain

  • Novartis Investigative Site

    RECRUITING

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Novartis Investigative Site

    RECRUITING

    Salamanca, Castille and León, 37007, Spain

  • Novartis Investigative Site

    RECRUITING

    Barcelona, Catalonia, 08035, Spain

  • Novartis Investigative Site

    RECRUITING

    Pamplona, Navarre, 31008, Spain

  • Novartis Investigative Site

    RECRUITING

    Barcelona, 08041, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28009, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28041, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28046, Spain

  • Novartis Investigative Site

    RECRUITING

    Seville, 41013, Spain

  • Novartis Investigative Site

    RECRUITING

    Valencia, 46010, Spain

  • Novartis Investigative Site

    RECRUITING

    Taipei, 10002, Taiwan

  • Novartis Investigative Site

    RECRUITING

    Birmingham, B15 2TH, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    London, SE5 9RS, United Kingdom

  • Ohio ST Compr Cancer Ctr James Hosp

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Oregon Health & Science University

    RECRUITING

    Portland, Oregon, 97239, United States

  • Oregon Health Sciences University

    RECRUITING

    Portland, Oregon, 97239, United States

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Stanford University Medical Center

    RECRUITING

    Stanford, California, 94304, United States

  • The Childrens Hosp of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Thomas Jefferson University

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • UCLA Medical Center

    RECRUITING

    Los Angeles, California, 90095, United States

  • UCSF Medical Center

    RECRUITING

    San Francisco, California, 94143, United States

  • UTSW/Children's Medical Center

    RECRUITING

    Dallas, Texas, 75235, United States

  • Uni Of Michigan Health System

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Uni of Chi Medi Ctr Hema and Onco

    RECRUITING

    Chicago, Illinois, 60637, United States

  • University of Chicago Medical Center, Hematology & Oncology

    RECRUITING

    Chicago, Illinois, 60637, United States

  • University of Kansas Cancer Center

    RECRUITING

    Westwood, Kansas, 66205, United States

  • University of Kansas Cancer Center SC

    RECRUITING

    Westwood, Kansas, 66205, United States

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109-2800, United States

  • University of Michigan Health System SC CTL019

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • University of Minnesota

    WITHDRAWN

    Minneapolis, Minnesota, 55455, United States

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • University of Pennsylvania

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • University of Texas Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75390, United States

  • University of Utah Clinical Trials Office

    RECRUITING

    Salt Lake City, Utah, 84108, United States

  • University of Utah Clinical Trials Office

    RECRUITING

    Salt Lake City, Utah, 84108, United States

  • University of Wisconsin Hospital

    RECRUITING

    Madison, Wisconsin, 53792, United States

  • University of Wisconsin Hospital and Clinics

    RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact Email: •••••@•••••

  • Wayne State University-Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Weill Cornell Medical College

    WITHDRAWN

    New York, New York, 10065, United States